Salidroside (Standard)

Salidroside (Standard) is the analytical standard of Salidroside. This product is intended for research and analytical applications. Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.

Product Specifications

CAS Number

[10338-51-9]

Product Name Alternative

Rhodioloside (Standard)

UNSPSC

12352005

Hazard Statement

H319

Target

Apoptosis; mTOR; PINK1/Parkin; Prolyl Endopeptidase (PREP) ; Reference Standards

Type

Reference Standards

Related Pathways

Apoptosis; Autophagy; Metabolic Enzyme/Protease; Neuronal Signaling; Others; PI3K/Akt/mTOR

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/salidroside-standard.html

Purity

99.82

Solubility

10 mM in DMSO

Smiles

O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1OCCC2=CC=C(O)C=C2

Molecular Formula

C14H20O7

Molecular Weight

300.30

Precautions

H319

References & Citations

[1]Wang Z, et al. Salidroside Ameliorates Furan-Induced Testicular Inflammation in Relation to the Gut-Testis Axis and Intestinal Apoptosis. J Agric Food Chem. 2023 Nov 9. |[2]Li R, et al. Salidroside Protects Dopaminergic Neurons by Enhancing PINK1/Parkin-Mediated Mitophagy. Oxid Med Cell Longev. 2019 Sep 10;2019:9341018.|[3]Fan W, et al. Prolyl endopeptidase inhibitors from the underground part of Rhodiola sachalinensis. Chem Pharm Bull (Tokyo) . 2001 Apr;49 (4) :396-401.|[4]Ju L, et al. Salidroside, A Natural Antioxidant, Improves β-Cell Survival and Function via Activating AMPK Pathway. Front Pharmacol. 2017 Oct 18;8:749.|[5]Chen X, et al. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activatingmTOR signalling. J Cachexia Sarcopenia Muscle. 2016 May;7 (2) :225-32.|[6]Wu L, et al. Salidroside Protects against MPP+-Induced Neuronal Injury through DJ-1-Nrf2 Antioxidant Pathway. Evid Based Complement Alternat Med. 2017;2017:5398542.